Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis

被引:16
|
作者
Farzanehfar, Parisa [1 ,2 ]
机构
[1] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia
[2] St Vincents Hosp, Fitzroy, Vic 3065, Australia
关键词
Adult neurogenesis; BrdU(+) cells; Midbrain; Parkinson's disease; Stem cells; Striatum; Substantia Nigra (SN); DEEP-BRAIN-STIMULATION; PRECURSOR CELL-PROLIFERATION; IMPULSE CONTROL DISORDERS; GROWTH-FACTOR-ALPHA; SUBSTANTIA-NIGRA; GENE-THERAPY; SUBVENTRICULAR ZONE; DOPAMINE NEURONS; NEUROTROPHIC FACTOR; PROGENITOR CELLS;
D O I
10.1007/s11064-016-2053-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The motor symptoms of Parkinson's disease (PD) are caused by degeneration of dopamine (DA) neurons in the substantia nigra pars compacta (SNc) of midbrain. Given the fact that current treatment options are mostly symptomatic and based on increasing DA level in the nigrostriatal system, it is generally believed the most effective and long-lasting treatment for PD motor symptoms will be replacing SNc DA cells, either by endogenous repair (i.e. neurogenesis) or cell transplantation. While cell transplantation is hindered by failure of acquisition and maintenance of the DA phenotype by transplanted cells, hope rests upon non-invasive cell replacement therapy (CRT) with endogenous neural stem cells, which have the potential to give rise to new neurons including DA neurons. Understanding underlying mechanisms and signalling pathways of neurogenesis in the adult brain could shed light on obstacles to achieve effective CRTs and better treatments for PD. This paper first reviews different therapeutic strategies in context of PD along with their advantages and disadvantages followed by an extensive review of adult neurogenesis.
引用
收藏
页码:3161 / 3170
页数:10
相关论文
共 50 条
  • [31] Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology
    Avazzadeh, Sahar
    Baena, Jara Maria
    Keighron, Cameron
    Feller-Sanchez, Yajaira
    Quinlan, Leo R.
    BRAIN SCIENCES, 2021, 11 (03)
  • [32] Towards a better understanding of social work practice in Parkinson's disease care
    Shurer, J.
    Guan, T.
    Zerden, L.
    Browner, N.
    Kreitzer, L.
    Book, E.
    MOVEMENT DISORDERS, 2021, 36 : S5 - S5
  • [33] Towards a better understanding of anticipatory postural adjustments in people with Parkinson's disease
    Seuthe, Jana
    Heinzel, Anna
    Hulzinga, Femke
    Ginis, Pieter
    Zeuner, Kirsten E.
    Deuschl, Guenther
    D'Cruz, Nicholas
    Nieuwboer, Alice
    Schlenstedt, Christian
    PLOS ONE, 2024, 19 (03):
  • [34] Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?
    Rehman, Saleha
    Nabi, Bushra
    Zafar, Ameeduzzafar
    Baboota, Sanjula
    Ali, Javed
    EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (12) : 1355 - 1366
  • [35] Sustained delivery of GDNF: towards a treatment for Parkinson's disease
    Zurn, AD
    Widmer, HR
    Aebischer, P
    BRAIN RESEARCH REVIEWS, 2001, 36 (2-3) : 222 - 229
  • [36] Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?
    Jost, Wolfgang H.
    Toenges, Lars
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (12) : 565 - 570
  • [37] The Adult Neurogenesis Theory of Alzheimer's Disease
    Abbate, Carlo
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 93 (04) : 1237 - 1276
  • [38] Adult neurogenesis and the pathogenesis of Alzheimer's disease
    Taupin, Philippe
    MEDICAL SCIENCE MONITOR, 2009, 15 (03): : LE1 - LE1
  • [39] Adult hippocampal neurogenesis in Alzheimer's disease
    Disouky, Ahmed
    Lazarov, Orly
    MOLECULAR BIOLOGY OF NEURODEGENERATIVE DISEASES: VISIONS FOR THE FUTURE, PT B, 2021, 177 : 137 - 156
  • [40] New insights in neurogenesis and neuroprotection in Parkinson's disease
    Isacson, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 324 - 325